top of page
Abstract Futuristic Background


Nammisomes: Image

Immune Modulating Prodrugs (IMPs)
The Key to Nammisome Success

  • All active agents are clinically validated molecules​

  • Prodrug design:

    • Enables efficient and stable incorporation into Nammisomes

    • Maintains immune modulating agents in an Inactive state until released by intracellular esterases

    • Provides IP and FTO

  • Mechanisms of validated prodrugs:​

    • Programmed cell death protein 1 (PD-1) Antagonist​

    • Toll Receptor (TLR)1/2 Agonist

    • Toll Receptor (TLR)4 Agonist

    • Toll Receptor (TLR)7 Agonist

    • Indoleamine 2,3-dioxygenase-1 (IDO-1) Antagonist

    • Adenosine 2A Receptor (A2AR) antagonist

    • Tumor Growth Factor Beta (TGF-β) inhibitor

Nammisomes: Features

Design of a Nammisome

Nammisomes: Features

Nammisomes: Designed to Tackle the Key Challenges of Immunotherapies

  1. Enables incorporation of multiple immunotherapy mechanisms of action into a single drug product , thereby enhancing efficacy and reducing development time/costs.

  2. Prodrug design and incorporation into Nammisome maintains immunotherapy in an inactive state in circulation and prevents ‘leaching’ of the agents from the nanoparticles, enhancing pharmacokinetics and preventing systemic immune activation.

  3. Physicochemical properties of Nammisomes are designed to allow them to avoid uptake by cells in circulation, while taking advantage of the abnormal and leaky vasculature of tumors to escape and accumulate within tumors.

Nammisomes: Features
bottom of page